Martin Reck
LungenClinic Grosshansdorf
2 papers in the Anchorcite directory, published between 2015 and 2016, cited 18,827 times in total.
ORCID profileResearch topics
- Cancer Immunotherapy and Biomarkers · 2 papers
- Lung Cancer Diagnosis and Treatment · 2 papers
- Lung Cancer Treatments and Mutations · 2 papers
Frequent co-authors
- Julie Renee Brahmer · 2 papers
- Delvys Rodríguez‐Abreu · 1 paper
- Andrew George Robinson · 1 paper
- Rina Hui · 1 paper
- Tibor Csőszi · 1 paper
- Andrea Fülöp · 1 paper
- Maya Gottfried · 1 paper
- Nir Peled · 1 paper
Papers
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung CancerNew England Journal of Medicine · 2016 · 10,276 citations
BACKGROUND: Pembrolizumab is a humanized monoclonal antibody against programmed death 1 (PD-1) that has antitumor activity in advanced non-small-cell lung cancer (NSCLC), with increased activity in tumors that express programmed death ligand 1 (PD-L1). METHODS: In this open-label, phase 3…
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung CancerNew England Journal of Medicine · 2015 · 8,551 citations
BACKGROUND: Patients with advanced squamous-cell non-small-cell lung cancer (NSCLC) who have disease progression during or after first-line chemotherapy have limited treatment options. This randomized, open-label, international, phase 3 study evaluated the efficacy and safety of nivolumab, a fully human IgG4…
Metadata from OpenAlex (CC0).